AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33333200
Drug: Conventional Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional Radiation Therapy (cRT) - 1 × 8 Gy, 5 × 4 Gy, or 10 × 3 Gy
Trial: 34091914
Drug: Stereotactic Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic Body Radiation Therapy (SBRT)
Trial: 32769914
Drug: NBP injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBP injection
Trial: 33290108
Drug: Dashboard driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dashboard driven infliximab dosing (precision group, PG)
Trial: 33290108
Drug: Standard infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard infliximab dosing (control group, CG)
Trial: 35131978
Drug: Balance training
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance training added to physical therapy
Trial: 35131978
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (control group)
Trial: 36440473
Drug: Intrathecal drug
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal drug delivery (IDD)
Trial: 36440473
Drug: Intrathecal compounded
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal compounded medications
Trial: 33346899
Drug: Surface treatment
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface treatment group
Trial: 33346899
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (TXA by intravenous drip combined with local injection into the articular cavity)
Trial: 33080291
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine
Trial: 32150549
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 6 weeks
Trial: 33938071
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group (HDM immunotherapy)
Trial: 33938071
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group (HDM immunotherapy) in younger individuals (16-30 years)
Trial: 32895353
Drug: Intra articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra articular Hyaluronic acid injections weekly for three weeks
Trial: 36942062
Drug: Enoxaparin 60
RxNorm normalized name: enoxaparin 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 60 mg daily
Trial: 36942062
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg daily (Control)
Trial: 36136263
Drug: Microfracture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microfracture treatment
Trial: 33323326
Drug: Intensive individualized
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive individualized nutrition counseling (3 monthly sessions)
Trial: 34379777
Drug: Error-Augmentation Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Error-Augmentation Training (EAT)
Trial: 32648392
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group
Trial: 35742573
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for cannabis cessation (CBT-CC)
Trial: 34453620
Drug: Ultra-low tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low tidal volume ventilation (3 ml/kg predicted body weight)
Trial: 34453620
Drug: Conventional ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilation (6 ml/kg predicted body weight)
Trial: 35238225
Drug: D-bread (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-bread (50 g/day, fortified with 1000 IU of vitamin D)
Trial: 35238225
Drug: D-supplement (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-supplement (1000 IU vitamin D)
Trial: 35238225
Drug: P-yogurt (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-yogurt (500 mL/day, plain yogurt)
Trial: 35152197
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by concurrent chemoradiotherapy
Trial: 37745479
Drug: High-dose propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose propofol
Trial: 33475663
Drug: Polymethoxyflavone purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymethoxyflavone purified from Kaempferia parviflora (12 mg per day for 12 weeks)
Trial: 39185955
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus Aspirin 100 mg once daily
Trial: 33357465
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g bolus, followed by continuous infusion of 1 g every 8 h, terminated immediately before aneurysm treatment, or 24 h after start of the medication)
Trial: 33879015
Drug: Isotonic intravenous
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic intravenous fluid (sodium chloride, 0.9%, and dextrose, 5%)
Trial: 33879015
Drug: Hypotonic intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic intravenous fluid (sodium chloride, 0.15%, and dextrose, 5%)
Trial: 32926462
Drug: Baricitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (all doses)
Trial: 32134754
Drug: Fixation time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixation time of 96 hours with SP142 antibody
Trial: 32134754
Drug: Fixation time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixation time of 96 hours with SP263 antibody
Trial: 32134754
Drug: SP142 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP142 antibody after 96 hours of fixation
Trial: 32134754
Drug: SP263 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP263 antibody after 96 hours of fixation
Trial: 34142567
Drug: Isotonic seawater
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic seawater spray containing chamomile liquid extract (Group A)
Trial: 34142567
Drug: Isotonic seawater
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic seawater spray (Group B)
Trial: 32618258
Drug: Preventive zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive zinc (PZ) tablets (7 mg/day)
Trial: 32618258
Drug: Therapeutic zinc
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic zinc (TZ) supplements for diarrhea treatment (20 mg/day for 10 days)
Trial: 32618258
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP; containing 10 mg zinc and 14 other micronutrients)
Trial: 34290965
Drug: Saffron (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (100 mg/day)
Trial: 32963047
Drug: Romilkimab 200
RxNorm normalized name: Romilkimab
DrugBank: Romilkimab (DB16318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romilkimab 200 mg subcutaneously once a week for 24 weeks
Trial: 38537780
Drug: Apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 2.5 mg twice daily
Trial: 32691672
Drug: BIOF2 (bioactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIOF2 (bioactive cell-free formulation)
Trial: 32271146
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual treatment)
Trial: 35063205
Drug: LCω3 (MAG‐EPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCω3 (MAG‐EPA 3 g daily)
Trial: 33094551
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 - 17% EDTA, Saline and 2% Chlorhexidine solution
Trial: 34499174
Drug: Multicomponent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent treatment (pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness, delivered in 2-hour weekly sessions for 12 weeks)
Trial: 34499174
Drug: Multicomponent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent treatment
Trial: 34499174
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (mainly pharmacological treatment)
Trial: 32391579
Drug: DFMO maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO maintenance therapy for HRNB after standard COG induction, consolidation and immunotherapy for 2 years
Trial: 32391579
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (76 HRNB patients treated at Beat Childhood Cancer Research Consortium hospitals, disease-free after standard therapy, no DFMO)
Trial: 34283997
Drug: 12-month, individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month, individually tailored, progressive, physiotherapist-supervised physical exercise twice a week (n=150)
Trial: 34851734
Drug: Fentanyl (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (75 µg)
Trial: 32197936
Drug: PSA-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA-based screening (two rounds at 4-6 year intervals, biopsy recommended if PSA>=3.0 ng/mL)
Trial: 35355827
Drug: Neutral Sodium
RxNorm normalized name: Neutral Sodium Fluoride Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral Sodium Fluoride (NaF) oral rinse (Colgate® PreviDent® Dental Rinse‐0.2% NaF) weekly for 6 months
Trial: 35355827
Drug: Acidulated Phosphate
RxNorm normalized name: Acidulated Phosphate Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidulated Phosphate Fluoride (APF) oral rinse (Colgate® Ortho Defense@ PhosFlur® Rinse‐0.044% w/v of NaF) daily for 6 months
Trial: 34147154
Drug: Dihydroartemisinin-piperaquine mass
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine mass drug administration (MDA) with a target total dose of 7 mg/kg dihydroartemisinin and 55 mg/kg piperaquine, delivered in three rounds over a period from March 4 to May 10, 2015.
Trial: 34028126
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus Capecitabine (L + C)
Trial: 33267723
Drug: Antihypertensive medications
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medications
Trial: 34548312
Drug: Procalcitonin guided
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin guided antibiotics (n=195)
Trial: 32331005
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (56 mg or 84 mg) in combination with newly initiated oral antidepressant (ESK+AD)
Trial: 32331036
Drug: Oral antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidepressant + placebo nasal spray (AD+PBO)
Trial: 35413861
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment thrice weekly for 4 weeks
Trial: 34881911
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (CPT)
Trial: 33833507
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 25 µg twice-daily (BID)
Trial: 33833507
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 25 µg BID
Trial: 32410424
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia (MA) therapy including oral administration of celecoxib before operation, local anesthetic wound infiltration during operation, and ice compression and oral administration of celecoxib after operation.
Trial: 32410424
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia (MA) therapy.
Trial: 32410424
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia pump (Control group).
Trial: 37045683
Drug: 2 +
RxNorm normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 + 1 schedule (two primary doses and a booster)
Trial: 37045683
Drug: 1 +
RxNorm normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 + 1 schedule (doses at 3 and 12 months)
Trial: 36316932
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nicotinamide 5 times a day for 2 days
Trial: 35315603
Drug: Viread® (tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viread® (tenofovir disoproxil fumarate) at a dose of 300 mg once daily for 48 weeks
Trial: 34459996
Drug: Daily Intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Intake of Metals (DIM) and Target Hazard Quotient (THQ)
Trial: 37465817
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: 34193504
Drug: Bromocriptine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (10 mg/day and 22.5 mg/day)
Trial: 38485487
Drug: Inhaled Nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide (NO)
Trial: 33933036
Drug: Ambulatory oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory oxygen therapy
Trial: 32687695
Drug: Sitafloxacin granules
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin granules 50 mg single dose
Trial: 32687695
Drug: Sitafloxacin granules
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin granules 100 mg single dose
Trial: 32687695
Drug: Sitafloxacin granules
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sitafloxacin granules 200 mg single dose
Trial: 37394178
Drug: EpiPen (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EpiPen (0.3 mg)
Trial: 34332429
Drug: Integrated Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Coping Awareness Therapy (I-CAT)
Trial: 33546045
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin Pill combined with Western medicine
Trial: 32768182
Drug: Fully guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully guided protocol (24 implants)
Trial: 32501868
Drug: OPRX-106 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPRX-106 2 mg administered orally once daily for 8 weeks
Trial: 32546198
Drug: Systematic HRQoL
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic HRQoL assessment using the CHES software before each consultation coupled with therapeutic information (three workshops related to understanding the prescription, nutrition, and fatigue)
Trial: 36042217
Drug: Hybrid closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid closed-loop insulin delivery system
Trial: 38985461
Drug: Edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 30 mg once daily
Trial: 99370165
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IFN plus ribavirin)
Trial: 36065528
Drug: Treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimen (specific medications not detailed)
Trial: 36065528
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for infertility (specific medications not detailed)
Trial: 35441466
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin produced by Bioton S.A. (0.3 units/kg)
Trial: 35789270
Drug: trastuzumab-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab-based therapy
Trial: 35789270
Drug: lapatinib-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lapatinib-based therapy
Trial: 35789270
Drug: trastuzumab-lapatinib-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab-lapatinib-based therapy
Trial: 35789270
Drug: trastuzumab-based neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab-based neoadjuvant therapy in NeoSphere cohort
Trial: 33070223
Drug: 1 mM
RxNorm normalized name: PhaSeal Protector, 21 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mM l-carnitine
Trial: 33070223
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without l-carnitine)
Trial: 32514794
Drug: Nasal glucagon
RxNorm normalized name: glucagon Nasal Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal glucagon (NG) 3 mg
Trial: 32514794
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon (IMG) 1 mg
Trial: 35831932
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (immunosuppressive therapy)
Trial: 33766759
Drug: Soshiho-tang (SSHT)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soshiho-tang (SSHT) administered three times a day for 4 weeks
Trial: 35060622
Drug: Dynamic panel
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic panel model using structural equation modeling (ML-SEM)
Trial: 39557549
Drug: In-person treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person treatment
Trial: 36315226
Drug: Bioptron light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioptron light therapy for 12 minutes three times per week plus standard wound care
Trial: 36240610
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of GH (SG), mean baseline GH dose of 0.13 mg/day increased to 0.31 mg/day at study end
Trial: 34707496
Drug: Ejiao (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ejiao (6 g/day)
Trial: 35575780
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard medication workflow)
Trial: 33847634
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) and methylene blue (MB) combination method
Trial: 34412906
Drug: Pictograms on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pictograms on prescription medication labels
Trial: 34412906
Drug: Pictograms for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pictograms for dose and route of administration, and dosage frequency
Trial: 34650034
Drug: Toripalimab plus
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab plus carboplatin and pemetrexed administered every three weeks for up to six cycles, followed by maintenance of toripalimab and pemetrexed.
Trial: 33569770
Drug: Azithromycin treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin treatment for 48 weeks
Trial: 37794803
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin with chemotherapy